MLYS vs. BBIO, ROIV, ELAN, MRNA, VRNA, RVMD, GRFS, RYTM, ABVX, and CYTK
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs. Its Competitors
BridgeBio Pharma (NASDAQ:BBIO) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.
Mineralys Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
BridgeBio Pharma has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500.
In the previous week, Mineralys Therapeutics had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 9 mentions for Mineralys Therapeutics and 7 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.71 beat Mineralys Therapeutics' score of 0.40 indicating that BridgeBio Pharma is being referred to more favorably in the media.
BridgeBio Pharma currently has a consensus price target of $63.94, indicating a potential upside of 22.10%. Mineralys Therapeutics has a consensus price target of $43.50, indicating a potential upside of 10.77%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Mineralys Therapeutics.
Mineralys Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
BridgeBio Pharma beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 9/22/2025 by MarketBeat.com Staff
